Confidential Information in Audits. Audits by Theravance or its designees may involve the disclosure of Confidential Information of Hospira or other customers of Hospira, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to Third Parties, [***], unless required by law and only then upon prior written notice to Hospira or to Theravance as the case may be.
Confidential Information in Audits. Audits by Orchid or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 5 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 5 and Orchid shall not (and shall ensure that its designated auditors do not) disclose any such Confidential Information to Third Parties, including, but not limited to, the FDA or other applicable Regulatory Authority, unless required by Applicable Law and only then upon prior written notice to Hospira in accordance with Section 5.1(iii).
Confidential Information in Audits. Audits pursuant to the foregoing may involve the transfer of Hospira’s Confidential Information to Cempra (including representatives of Cempra’s Affiliates, or Cempra’s or its Affiliates’ licensees or sublicensees), and any such Confidential Information shall be subject to the terms of Article 11 hereof. Cempra shall ensure that any of the foregoing persons not in privity to or with this Agreement shall have signed an agreement containing terms and conditions regarding the non-disclosure and non-use of Confidential Information that are not materially less restrictive as those under this Agreement. The results of such audits and inspections shall, subject to the exceptions set forth in Section 1.15, be considered Confidential Information and shall not be disclosed to Third Parties, including the FDA, Health Canada and the EMA, unless required by law or as otherwise permitted under Article 11, and only then upon prior written notice to Hospira.
Confidential Information in Audits. Audits by Genzyme or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to Third Parties, excluding the FDA, unless required by law and only then upon prior written notice to Hospira.
Confidential Information in Audits. Audits by Xxxxxxx or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to Third Parties, including the FDA and any other relevant Regulatory Authority, unless required by law and only then upon prior written notice to Pfizer.
Confidential Information in Audits. Audits by Durata or its designees may involve the transfer of Confidential Information of a Party, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information of Hospira under Article 11 and shall not be disclosed to Third Parties, including, but not limited to, the FDA; EMA; Health Canada, unless required by applicable law, rules or regulations and only then upon prior written notice to Hospira to the extent permitted by applicable laws, rules or regulations.
Confidential Information in Audits. Audits by Revance or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 10 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 10 and shall not be disclosed to third parties, including, but not limited to, the FDA, unless required by law and only then upon prior written notice to Hospira. Hospira also agrees to allow the FDA to conduct any audit which the FDA requires and Hospira agrees to reasonably cooperate with the FDA in connection with such audit. Revance shall have the right to be on site during a pre-approval inspection for the Product, but may only directly participate in the inspection if requested by the FDA or Hospira. However, if any additional inspections are requested or required by or for any other Regulatory Authority, Hospira shall be entitled to an additional fee of [***] per each such Regulatory Authority inspection.
Confidential Information in Audits. Audits by AMAG or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to Third parties, […***…], unless required by law and only then upon prior written notice to Pfizer.
Confidential Information in Audits. Audits by Kythera or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to third parties, including, but not limited to, the FDA, unless required by law and only then upon prior written notice to Hospira.
Confidential Information in Audits. Audits by Xxxxxxx or its designees may involve the transfer of Confidential Information, and any such Confidential Information shall be [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to Third Parties, including the FDA and any other relevant Regulatory Authority, unless required by law and only then upon prior written notice to Pfizer.
